Cosmetic cross-reference

Cannabigerol

CAS 25654-31-3

Cannabigerol (CAS 25654-31-3) is a Phase 2 pharmaceutical compound with 4 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Cannabigerol

CAS Number

25654-31-3

UNII

J1K406072N

InChIKey

QXACEHWTBCFNSA-SFQUDFHCSA-N

ChEMBL ID

CHEMBL497318

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural product

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2

Mid-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL497318 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 4 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	IC50	23548.695652173912 nM	23	-
-	EC50	3027.2727272727275 nM	11	-
-	Ki	1194.4444444444443 nM	9	-
-	MIC	1.4375 ug.mL-1	8	-

SOURCE IUPHAR/BPS 6 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
Na v 1.7 SCN9A	Channel blocker	5.340000152587891 pIC50	35297036
Na v 1.7 SCN9A	Channel blocker	4.730000019073486 pIC50	35297036
Na v 1.8 SCN10A	Channel blocker	5.300000190734863 pIC50	39835903
TRPA1 Trpa1	Agonist	6.150000095367432 pEC50	38408345
TRPM8 Trpm8	Antagonist	6.800000190734863 pIC50	38408345
TRPM8 Trpm8	Antagonist	-	21902175

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Cannabigerol used for in pharmaceutical contexts?

Cannabigerol (CAS 25654-31-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Cannabigerol?

No adverse-event association or SIDER side-effect rows are rendered for Cannabigerol in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Cannabigerol also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Cannabigerol with EU status "permitted".

What clinical phase is Cannabigerol in?

Cannabigerol is rendered with ChEMBL max phase 2.